表紙:異染性白質ジストロフィー治療の世界市場(2022年~2029年)
市場調査レポート
商品コード
1082815

異染性白質ジストロフィー治療の世界市場(2022年~2029年)

Global Metachromatic leukodystrophy Treatment Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 160 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
異染性白質ジストロフィー治療の世界市場(2022年~2029年)
出版日: 2022年06月03日
発行: DataM Intelligence
ページ情報: 英文 160 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の異染性白質ジストロフィー治療について調査分析し、市場の概要とともに、市場動向、市場促進・抑制要因、COVID-19の影響、業界分析、セグメント別・地域別の市場分析、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 世界の異染性白質ジストロフィー治療市場:範囲と調査手法

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の異染性白質ジストロフィー治療市場:市場の定義と概要

第3章 世界の異染性白質ジストロフィー治療市場:エグゼクティブサマリー

  • タイプ別の市場内訳
  • 診断別の市場内訳
  • 治療タイプ別の市場内訳
  • エンドユーザー別の市場内訳
  • 地域別の市場内訳

第4章 世界の異染性白質ジストロフィー治療市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の異染性白質ジストロフィー治療市場:業界分析

  • サプライチェーン分析
  • 価格分析
  • アンメットニーズ

第6章 世界の異染性白質ジストロフィー治療市場:COVID-19分析

  • 市場へのCOVID-19の影響分析
    • COVID-19前の市場シナリオ
    • 現在のCOVID-19の市場シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19における価格変動
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • 結論

第7章 世界の異染性白質ジストロフィー治療市場:タイプ別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場魅力指数:タイプ別
  • 乳児後期型異染性白質ジストロフィー
    • イントロダクション
    • 市場規模分析・前年比成長分析(%):2020年~2029年、および2021年~2029年(百万米ドル)
  • 若年型異染性白質ジストロフィー
  • 成人型異染性白質ジストロフィー

第8章 世界の異染性白質ジストロフィー治療市場:診断別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場魅力指数:タイプ別
  • 血液検査
    • イントロダクション
    • 市場規模分析・前年比成長分析(%):2020年~2029年、および2021年~2029年(百万米ドル)
  • 遺伝子検査
  • 神経伝導検査
  • 磁気共鳴画像法(MRI)
  • 心理的および認知的テスト
  • その他

第9章 世界の異染性白質ジストロフィー治療市場:治療タイプ別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場魅力指数:治療タイプ別
  • 薬物療法
    • イントロダクション
    • 市場規模分析・前年比成長分析(%):2020年~2029年、および2021年~2029年(百万米ドル)
  • 遺伝子治療
    • AGT-183
    • GSK-2696274
    • その他
  • 酵素補充療法または強化療法
  • 基質減少療法
  • その他

第10章 世界の異染性白質ジストロフィー治療市場:エンドユーザー別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):エンドユーザー別
    • 市場魅力指数:エンドユーザー別
  • 病院
    • イントロダクション
    • 市場規模分析・前年比成長分析(%):2020年~2029年、および2021年~2029年(百万米ドル)
  • クリニック
  • 診断センター
  • その他

第11章 世界の異染性白質ジストロフィー治療市場:地域別

  • イントロダクション
    • 地域別の市場規模分析・前年比成長分析(%):2020年~2029年、および2021年~2029年(百万米ドル)
    • 地域別の市場魅力指数
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):診断別
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場規模分析・前年比成長分析(%):エンドユーザー別
    • 市場規模分析・前年比成長分析(%):国別
  • 欧州
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):診断別
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場規模分析・前年比成長分析(%):エンドユーザー別
    • 市場規模分析・前年比成長分析(%):国別
  • 南米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):診断別
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場規模分析・前年比成長分析(%):エンドユーザー別
    • 市場規模分析・前年比成長分析(%):国別
  • アジア太平洋
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):診断別
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場規模分析・前年比成長分析(%):エンドユーザー別
    • 市場規模分析・前年比成長分析(%):国別
  • 中東とアフリカ
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):診断別
    • 市場規模分析・前年比成長分析(%):治療タイプ別
    • 市場規模分析・前年比成長分析(%):エンドユーザー別

第12章 世界の異染性白質ジストロフィー治療市場:競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業のリスト

第13章 世界の異染性白質ジストロフィー治療市場:企業プロファイル

  • ArmaGen, Inc.
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主要ハイライト
    • 財務概要
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Orchard Therapeutics plc
  • Magenta Therapeutics
  • Recursion Pharmaceuticals Inc.
  • RegenxBio Inc.

第14章 世界の異染性白質ジストロフィー治療市場:DataM

目次
Product Code: DMPH5227

Market Overview

The global metachromatic leukodystrophy treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Metachromatic leukodystrophy is a rare hereditary (genetic) condition characterized by the accumulation of fatty substances (lipids) in cells, mainly in the brain, spinal cord, and peripheral nerves. A lack of an enzyme that helps break down lipids called sulfatides causes this accumulation. Because the substance that covers and protects nerve cells (myelin) is destroyed, the brain and nervous system gradually lose function. Metachromatic leukodystrophy is currently incurable. Early detection and treatment may help manage some signs and symptoms and postpone the progression of the illness, depending on the form and age of start.

Market Dynamics

Innovation in the products for treating demyelinating conditions is expected to drive market growth.

Joanne Kurtzberg an American professor of pediatrics and pathology at Duke University has developed a product called Duke O Cell or DUOC-01, which is a cell generated from umbilical cord blood that has been demonstrated to help people with demyelinating diseases. It's been used as a bridge therapy to help youngsters with inherited metabolic problems engraft faster. Moreover, Atidarsagene autotemcel (arsa-cel) is a gene therapy medicinal product based on autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a lentiviral vector encoding the ARSA cDNA driving supranormal ARSA expression in HSPCs and their progeny, with preliminary evidence of safety and efficacy in patients with early-onset MLD. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of therapies for the treatment of Metachromatic leukodystrophy and there is no single FDA-approved pharmacological product on the market that can completely cure metachromatic leukodystrophy are the factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Standard operating procedures for Personal Protective Equipment (PPE) for home care nurses were unclear during the pandemic. The doctors contacted all patients by email or telephone, as well as sent letters to those who did not have access to email or the internet. With little evidence of the impact of SARS-CoV-2 infections on rare diseases early in the pandemic, we decided that the danger of developing SARS-CoV-2 outweighed the risk of treatment interruption. Moreover, disruptions in therapy, whether planned or inevitable, resulted in a deterioration of clinical parameters and quality of life, as well as potentially negative outcomes such as cardiac events and/or renal function decline.

Additionally, the severity of the impact of the COVID-19 pandemic on business, including on preclinical and clinical development, its supply chain, and commercial programs got affected. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Gene Therapy segment is expected to hold the largest market share in metachromatic leukodystrophy treatment market

The gene therapy segment is expected to dominate in 2021. The segment's growth is beneficial because gene therapy showed benefits in pediatric patients with early-onset metachromatic leukodystrophy (MLD). There is currently no cure for MLD. In contrast, the European Medicines Agency (EMA) has recommended that the gene therapy Libmeldy, which consists of cryopreserved autologous CD34+ cells encoding the arylsulfatase-A gene, be given marketing authorization in the European Union to treat metachromatic leukodystrophy (MLD), a rare inherited metabolic disease that affects the nervous system. Libmeldy is for children who have been diagnosed as carriers of the faulty gene but have not yet shown symptoms and have the 'late infantile' or 'early juvenile' variants of MLD. It is used in children who have been diagnosed with the early juvenile form of the disease and have begun to show symptoms while still being able to walk independently and before cognitive impairment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global metachromatic leukodystrophy treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of metachromatic leukodystrophy, increased number of diagnosed patients, ongoing clinical trials, rise in government funding for research & development for the treatment, and launch of contact registry by the organizations in the region are some of the factors the market is expected to boost in the forecast period. For instance, metachromatic leukodystrophy ranges from 1/40,000 births in the United States of America. Moreover, The National Organization for Rare Disorders, Inc. has initiated a large-scale study to investigate Metachromatic Leukodystrophy (MLD), a brain disease that causes irreparable white matter destruction. The Metachromatic Leukodystrophy Community United Research and Engagement Survey (MLDCures) is a new project that provides a platform for Metachromatic Leukodystrophy patients worldwide to contribute information about the disease (MLD). Its goal is to create an international resource that scientists can use in future research. Additionally, Cure MLD is collaborating on the study with the National Organization for Rare Disorders (NORD), an independent organization that developed the IAMRARE platform to aid in the identification and treatment of all 7,000 rare diseases. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the metachromatic leukodystrophy treatment market are ArmaGen, Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc, Magenta Therapeutics, Recursion Pharmaceuticals Inc. and RegenxBio Inc.

ArmaGen, Inc.:

Overview:

ArmaGen is a privately held, clinical-stage biotechnology company, with headquarters and research operations located in Calabasas, CA focused on developing revolutionary therapies for severe neurological disorders. The company is advancing innovative therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimer's and Parkinson's. Moreover, ArmaGen has eight compounds in development. The company's lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials and AGT-181 for Hurler syndrome, which is in Phase 2 trials. The company is advancing its pipeline through licensing and collaboration agreements, in-house development efforts, and future partnering opportunities.

­Product Portfolio:

AGT-183: AGT-183 is an investigational enzyme replacement therapy (ERT) for the treatment of metachromatic leukodystrophy (MLD), a lysosomal storage disease that arises from a deficiency of the enzyme arylsulfatase (ASA).

Why Purchase the Report?

Visualize the composition of the metachromatic leukodystrophy treatment market segmentation by type, diagnosis, treatment type, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in metachromatic leukodystrophy treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of metachromatic leukodystrophy treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global metachromatic leukodystrophy treatment market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment Type
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovation in the products for treating demyelinating conditions is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of therapies for the treatment of Metachromatic leukodystrophy is expected to hamper the market growth in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Late-Infantile MLD*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Juvenile MLD
  • 7.4. Adult MLD

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Blood tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Genetic tests
  • 8.4. Nerve conduction study
  • 8.5. Magnetic resonance imaging (MRI)
  • 8.6. Psychological and cognitive tests
  • 8.7. Others

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 9.2. Pharmacotherapy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Gene Therapy
    • 9.3.1. AGT-183
    • 9.3.2. GSK-2696274
    • 9.3.3. Others
  • 9.4. Enzyme replacement or enhancement therapy
  • 9.5. Substrate reduction therapy
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Diagnostic Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. ArmaGen, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. GlaxoSmithKline plc
  • 13.3. Takeda Pharmaceutical Company Limited
  • 13.4. Orchard Therapeutics plc
  • 13.5. Magenta Therapeutics
  • 13.6. Recursion Pharmaceuticals Inc.
  • 13.7. RegenxBio Inc.

LIST NOT EXHAUSTIVE

14. Global Metachromatic leukodystrophy Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us